期刊论文详细信息
Frontiers in Medicine
Challenges in the Management of SARS-CoV2 Infection: The Role of Oral Bacteriotherapy as Complementary Therapeutic Strategy to Avoid the Progression of COVID-19
article
Gabriella d'Ettorre1  Carolina Scagnolari2  Cristina Mastropietro1  Vito Trinchieri1  Gregorio Egidio Recchia1  Vera Mauro1  Guido Antonelli2  Francesco Pugliese3  Claudio Maria Mastroianni1  Giancarlo Ceccarelli1  Massimiliano Marazzato1  Giuseppe Campagna4  Claudia Pinacchio1  Francesco Alessandri3  Franco Ruberto3  Giacomo Rossi5  Luigi Celani1 
[1] Department of Public Health and Infectious Diseases, Sapienza University of Rome;Laboratory of Virology, Department of Molecular Medicine, Affiliated to Istituto Pasteur Italia - Cenci Bolognetti Foundation, Sapienza University;Department of Anesthesia and Intensive Care Medicine, Sapienza University of Rome;Department of Clinical and Molecular Medicine, Sapienza University of Rome;School of Biosciences, Veterinary Medicine University of Camerino
关键词: COVID-19;    SARS-CoV-2;    bacteriotherapy;    probiotic;    lactobacillus;    gut-lung axis;    gut;   
DOI  :  10.3389/fmed.2020.00389
学科分类:社会科学、人文和艺术(综合)
来源: Frontiers
PDF
【 摘 要 】

Background: Gastrointestinal disorders are frequent in COVID-19 and SARS-CoV-2 has been hypothesized to impact on host microbial flora and gut inflammation, infecting intestinal epithelial cells. Since there are currently no coded therapies or guidelines for treatment of COVID-19, this study aimed to evaluate the possible role of a specific oral bacteriotherapy as complementary therapeutic strategy to avoid the progression of COVID-19. Methods: We provide a report of 70 patients positive for COVID-19, hospitalized between March 9th and April 4th, 2020. All the patients had fever, required non-invasive oxygen therapy and presented a CT lung involvement on imaging more than 50%. Forty-two patients received hydroxychloroquine, antibiotics, and tocilizumab, alone or in combination. A second group of 28 subjects received the same therapy added with oral bacteriotherapy, using a multistrain formulation. Results: The two cohorts of patients were comparable for age, sex, laboratory values, concomitant pathologies, and the modality of oxygen support. Within 72 h, nearly all patients treated with bacteriotherapy showed remission of diarrhea and other symptoms as compared to less than half of the not supplemented group. The estimated risk of developing respiratory failure was eight-fold lower in patients receiving oral bacteriotherapy. Both the prevalence of patients transferred to ICU and mortality were higher among the patients not treated with oral bacteriotherapy. Conclusions: A specific bacterial formulation showed a significant ameliorating impact on the clinical conditions of patients positive for SARS-CoV-2 infection. These results also stress the importance of the gut-lung axis in controlling the COVID-19 disease.

【 授权许可】

CC BY   

【 预 览 】
附件列表
Files Size Format View
RO202108180002063ZK.pdf 485KB PDF download
  文献评价指标  
  下载次数:2次 浏览次数:0次